ArticlePloS one2025
Exploring the impact of antibody-dependent cellular phagocytosis-related genes on the prognosis of metastatic melanoma.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastatic melanoma is a challenging clinical condition with poor prognosis. Recent research has highlighted the role of antibody-dependent cellular phagocytosis (ADCP) in tumor immunity, suggesting prognostic implications for ADCP-related genes (ARGs). This study develops a prognostic model for metastatic melanoma using ARGs to enhance clinical decision-making and therapeutic strategies.
methodsPrognostic ARGs were identified from the GSE46517 and GSE7553 datasets. A prognostic model was constructed using LASSO-Cox regression and validated across multiple cohorts, including TCGA and GEO datasets. A nomogram was developed to assess survival outcomes in metastatic melanoma patients. Functional assays, including siRNA knockdown of DOCK10 in A375 cells, were conducted to validate the role of DOCK10 in melanoma progression.
resultsA prognostic model based on six ARGs-NDRG1, HRAS, KPNA2, ICAM1, DOCK10, and CDC20-was developed. Patients were stratified into high- and low-risk groups based on risk scores, with high-risk patients showing poorer overall survival (OS) in both validation cohorts. The model was validated as an independent prognostic factor. Gene set enrichment analysis (GSEA) indicated that the low-risk group was enriched in immune-related pathways. High-risk patients exhibited higher genomic instability, which was associated with poorer prognosis. Knockdown of DOCK10 in A375 cells significantly reduced proliferation, migration, and invasion, confirming its role in melanoma progression.
conclusionThe model also demonstrated associations with immune cell infiltration and drug sensitivity, highlighting its potential utility in optimizing immunotherapy and chemotherapy strategies. This study developed a novel ARG-based prognostic model that aids in survival prediction and therapeutic decision-making for metastatic melanoma patients. DOCK10 was identified as a potential therapeutic target in melanoma metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.